Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
CJC-1295 is not FDA approved for general use, so patients should avoid self-sourcing or guessing dosage
Safety considerations: GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Postmarketing Experience The following adverse reactions have been reported: Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine
Did you hear the one about the researcher who went to Arizona and discovered Byetta
Patient Educ
It is not a hormone, not a peptide hormone analog, and not approved for any human therapeutic use by any regulatory authority as of 2025
US$ 23.60
US$ 25.35
